Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Borg

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2020
Mechanism and site of action of big dynorphin on ASIC1aChristian B Borg, Nina Braun, Stephanie A Heusser, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2010
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine responseY Rotman, B B Borg, A Soza, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 7, 2009
Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppressionTara N Palmore, Neeral L Shah, Rohit Loomba, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2007
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infectionYing Huang, Huiying Yang, Brian B Borg, et al.
Hepatology (Baltimore, Md.)|August 1, 2018
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal HypertensionGuadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Hepatology (Baltimore, Md.)|November 10, 2020
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHRohit Loomba, Mazen Noureddin, Kris V Kowdley, et al.
British Journal of Anaesthesia|December 23, 2019
Integration of the Duke Activity Status Index into preoperative risk evaluation: a multicentre prospective cohort studyDuminda N Wijeysundera, W Scott Beattie, Graham S Hillis, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Proceedings of the National Academy of Sciences of the United States of America|March 14, 2020
Mechanism and site of action of big dynorphin on ASIC1aChristian B Borg, Nina Braun, Stephanie A Heusser, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2010
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine responseY Rotman, B B Borg, A Soza, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 7, 2009
Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppressionTara N Palmore, Neeral L Shah, Rohit Loomba, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 12, 2007
A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infectionYing Huang, Huiying Yang, Brian B Borg, et al.
Hepatology (Baltimore, Md.)|August 1, 2018
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal HypertensionGuadalupe Garcia-Tsao, Michael Fuchs, Mitchell Shiffman, et al.
Alimentary Pharmacology & Therapeutics|October 31, 2023
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitisMarlyn J Mayo, John M Vierling, Christopher L Bowlus, et al.
Hepatology (Baltimore, Md.)|November 10, 2020
Combination Therapies Including Cilofexor and Firsocostat for Bridging Fibrosis and Cirrhosis Attributable to NASHRohit Loomba, Mazen Noureddin, Kris V Kowdley, et al.
British Journal of Anaesthesia|December 23, 2019
Integration of the Duke Activity Status Index into preoperative risk evaluation: a multicentre prospective cohort studyDuminda N Wijeysundera, W Scott Beattie, Graham S Hillis, et al.
Pageof 10